GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Total Liabilities

Regeneron Pharmaceuticals (WBO:REGN) Total Liabilities : €7,321 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Total Liabilities?

Regeneron Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2024 was €7,321 Mil.

Regeneron Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2023 (€6,517.21 Mil) to Mar. 2024 (€6,788.22 Mil) and increased from Mar. 2024 (€6,788.22 Mil) to Jun. 2024 (€7,321.45 Mil).

Regeneron Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€5,899.41 Mil) to Dec. 2022 (€6,183.67 Mil) and increased from Dec. 2022 (€6,183.67 Mil) to Dec. 2023 (€6,517.21 Mil).


Regeneron Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Regeneron Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Total Liabilities Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,343.95 5,045.44 5,899.41 6,183.67 6,517.21

Regeneron Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,128.35 6,801.59 6,517.21 6,788.22 7,321.45

Regeneron Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Regeneron Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3139.258+(2478.559+783.21
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+116.184+0)
=6,517

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=30334.543-23817.333
=6,517

Regeneron Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3259.489+(2511.644+1359.314
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+191.002+0)
=7,321

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=33524.637-26203.188
=7,321

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).